Higher Health Care Resource Utilization, Costs Associated With Renal Impairment in Multiple Myeloma

05/17/18

A new real-world study compared the health care resource utilization (HRU) and costs between patients treated for multiple myeloma with and without renal impairment.

The study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 1-5, 2018; Chicago, IL).

Renal impairment is a common treatment complication of multiple myeloma that can lead to significant morbidity. Limited real-world data exist on the economic burden of renal impairment in patients treated for multiple myeloma.

Rohan Medhekar, Health Economics Manager, Amgen (Thousand Oaks, CA), and colleagues attempted to compare the HRU and costs between patients treated for multiple myeloma with renal impairment and those without renal impairment. The retrospective analysis identified 2158 adult patients with renal impairment treated for multiple myeloma from 2006 through 2016. Patients were propensity score matched (1:1) to non-renal impairment patients based on demographics, baseline clinical variables, and costs

Patients had continuous enrollment for 12 months prior to and 3 months after index and were followed until the earliest of inpatient death, end of data, or enrollment. Average per patient per year all-cause HRU and costs (2016 US dollars) were compared between renal impairment and non-renal impairment patients.

-----

Related Content

Health Care Resource Use, Clinical Management of Advanced NSCLC Vary By Country

Navigating the Labyrinth of Multiple Myeloma Treatment

-----

Results of the comparison showed that compared with non-renal impairment patients, those with renal impairment had significantly higher per patient per year all-cause HRU, as well as inpatient ($92,011 vs $141,236), outpatient ($91,689 vs $140,163), and total costs ($152,196 vs $225,246).

Among propensity score-matched patients treated for multiple myeloma, renal impairment is associated with significant economic burden by way of higher all-cause HRU and costs, researchers concluded. “Supportive care for renal impairment management and treatment with evidence-based antimyeloma therapy is crucial for these patients,” they added.—Zachary Bessette